Novo Nordisk has cut its sales and profits forecasts for 2025 due to lower demand in the US for blockbuster weight loss and ...

Sarepta’s stock dropped by 26% after the FDA named a vocal critic of its gene therapy programme to lead its biologics ...

Venture philanthropy organisation Solve FSHD has announced an investment of $3m in Armatus Bio to support the development of ...

Discussing AstraZeneca’s experience with the Project Orbis pathway, Sabine Ledderhose, head of regulatory affairs for the ...

The European Commission (EC) has approved AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) ...

Developing orphan drugs involves navigating intricate regulatory landscapes, financial risks, and limited clinical data. To ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

Mergers and acquisitions (M&As) in the biopharmaceutical industry surged 101% in total deal value in the first quarter (Q1) ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

The options are for the freeze-dried version of Bavarian Nordic’s Jynneos, a formulation that allows easier stockpiling.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), once focused on treating diabetes and obesity, are now emerging as ...

Bristol Myers Squibb (BMS) plans to invest $40bn in the US over the next five years to bolster its research and manufacturing ...